Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Krüppel-like factor 16 (KLF16)
- Target
- KLF16
- Molecular classification
- Transcription factor, C2H2-type zinc finger protein
01
Overview
Krüppel-like factor 16 (KLF16) is a C2H2-type zinc finger transcription factor with affinity for GC-rich DNA sequences. It regulates gene expression in metabolic, endocrine, reproductive, and oncogenic pathways, operating both as a repressor and activator via recruitment of histone deacetylase (Sin3/HDAC) or acetyltransferase (p300/HAT) complexes. Mechanistically, KLF16’s activity and nuclear localization are influenced by phosphorylation, particularly by Src-family kinases. Biologically, KLF16 modulates osteogenic differentiation, is involved in tumorigenesis across several cancers, and serves as a potential prognostic biomarker. It does not have known interacting drugs, but its role as a gene regulator makes it a promising candidate for future therapeutic intervention
- Other names
- BTEB4NSLP2DRRFBasic transcription element-binding protein 4Dopamine receptor regulating factorNovel Sp1-like zinc finger transcription factor 2Transcription factor NSLP2Kruppel like factor 16
02
Biological functions
Gene silencing and activation by interacting with histone acetyltransferase and histone deacetylase complexesRegulation of metabolic and endocrine genes, notably in sex steroid-sensitive uterine cellsInhibition of osteogenic differentiation and bone formation, affecting cell growth and deathRegulation of cell proliferation, migration, invasion in cancer
03
Disease associations
Cancer (prostate, gastric, breast cancer)Endocrine and reproductive disordersBone-related diseases (inhibitor of osteogenesis)Metabolic diseases
04
Safety considerations
No specific safety concerns reported for direct targeting; however, modulation could impact broad transcriptional regulatory networks, affecting cell growth, differentiation, and endocrine/metabolic homeostasis
05
Biomarkers
Expression level of KLF16 in breast, prostate, and other tumors may serve as a biomarker for prognosis or disease progressionMAGT1 expression as a downstream effector in breast cancer
Beyond the preview
Go deeper on Krüppel-like factor 16 (KLF16).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Krüppel-like factor 16 (KLF16).